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ABSTRACT
Purpose: This paper describes the rationale, study design and procedures of the National Eye
Survey of Trinidad and Tobago (NESTT). The main objective of this survey is to obtain prevalence
estimates of vision impairment and blindness for planning and policy development.
Methods: A population-based, cross-sectional survey was undertaken using random multistage
cluster sampling, with probability-proportionate-to-size methods. Eligible participants aged 5 years
and older were sampled from the non-institutional population in each of 120 cluster segments.
Presenting distance and near visual acuity were screened in their communities. People aged 40
years and older, and selected younger people, were invited for comprehensive clinic assessment.
The interview included information on potential risk factors for vision loss, associated costs and quality
of life. The examination included measurement of anthropometrics, blood glucose, refraction, ocular
biometry, corneal hysteresis, and detailed assessment of the anterior and posterior segments, with
photography and optical coherence tomography imaging. Adult participants were invited to donate
saliva samples for DNA extraction and storage.
Results: The fieldwork was conducted over 13 months in 2013–2014. A representative sample of
10,651 individuals in 3410 households within 120 cluster segments identified 9913 people who were
eligible for recruitment.
Conclusion: The study methodology was robust and adequate to provide the first population-
based estimates of the prevalence and causes of visual impairment and blindness in Trinidad and
Tobago. Information was also gathered on risk factors, costs and quality of life associated with
vision loss, and on normal ocular parameters for the population aged 40 years and older.
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Introduction
The Global Burden of Disease (GBD) Study estimated that,
in 2010, 32.4 million people worldwide were blind and 191
million were moderately or severely visually impaired.1
Around 80% of vision loss is avoidable, through cost-
effective interventions to prevent, screen and treat sight-
threatening eye disease.2 Avoidable vision loss remains a
key public health concern.2 The GBD study also modeled
vision loss prevalence by region and country, but high-
lighted the paucity of population-based data in the
Caribbean region (Table 1).3–12 In addition to knowing
the prevalence of vision loss, epidemiological data on the
risks, impacts and costs of vision loss on individuals and
society are also important. Such country-specific data pro-
vides a robust foundation for the development of evidence-
based policies and services which aim to reduce avoidable
blindness and to support people with vision loss to achieve
their full potential.2
There was no previous population-based data on vision
loss in Trinidad and Tobago, a high-income, twin island
republic in the Caribbeanwith a population of 1.3million13
and a total landmass of 5128 km2. Expenditure on health-
care accounts for 4.8% of gross domestic product and eye
care services are available from both the private and public
health sector.14 Several factors suggested that the popula-
tion was at particular risk of sight-threatening eye disease.
First, the demographic profile is that of an aging
population,13 and with age the frequencies of cataract,
glaucoma and other age-related eye diseases increase.15
Second, the population has a unique and heterogeneous
ethnic mix,13 which may put it at increased genetic risk of
certain eye diseases.16–18 Furthermore, there is an emerging
epidemic of chronic non-communicable diseases, which
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are associated with ocular complications. An estimated
56% of the adult population is overweight or obese,
26–30% are hypertensive, and 19–21% have diabetes
mellitus.19,20 Recognizing the value of country-specific
data to inform a national eye care strategy, the Ministry
of Health of the Government of Trinidad and Tobago
approved funding for a National Eye Survey in 2012. This
paper outlines the rationale, study design and procedures
of the National Eye Survey of Trinidad and Tobago
(NESTT).
Materials and methods
Study design
The NESTT was a population-based, cross-sectional sur-
vey of the population aged 5 years and older. The study
was conducted through a collaboration between Anglia
Ruskin University (United Kingdom), and the University
of the West Indies (Trinidad and Tobago). An ancillary
genetic epidemiology study was conducted in collabora-
tion with Duke University (United States of America).
Aims
Primary objective
To estimate the prevalence of presenting blindness and
vision impairment among adults aged 40 years and
older.
Secondary objectives in persons aged 40 years and
older
(1) To determine the principal cause and risk factors
associated with blindness and moderate or severe vision
impairment (MSVI); (2) To estimate the prevalence of
common eye conditions; (3) To establish a normative
database of various biometric and ocular parameters; (4)
To explore the cost and impact of vision impairment on
quality of life; (5) To investigate the availability of low
vision rehabilitation services and barriers to uptake; (6)
To investigate the effectiveness of eye care services,
including cataract surgical coverage and cataract surgical
rate; (7) To establish a bio repository of saliva DNA
samples to enable future genome-wide association studies
of ocular and cardiovascular disease.
In addition, we aim to estimate the prevalence and
causes of presenting blindness and MSVI in people
aged 5–39 years.
Participants
The total population of Trinidad and Tobago was
1,328,019 in 2011, and the non-institutionalized
population was 1,322,546.13 An eligible person was
defined as someone resident in Trinidad or Tobago
for more than 6 months, who was aged 5 years or
older at their last birthday, and who was a usual
resident of the selected household. The last was
defined as sleeping in the household most nights of
the week and sharing at least one daily meal with
other household members.13 People currently abroad
or in an institution (e.g. hospital, prison) and not
anticipated to return within one month were
excluded.
Sample size
The study population required to address the primary
objective comprised individuals aged 40 years and
older. The Barbados Eye Survey suggested an expected
prevalence (p) of best-corrected blindness of 1.7%.4 The
sample size was chosen to achieve a desired level of
absolute precision (d) of 0.5% in the width of the 95%
confidence interval, and a design effect (DEFF) of 1.4;
n ¼ 1:96
2 pð1  pÞðDEFFÞ
d2
The sample was adjusted for a potential non-response
of 20%, based on the Barbados Eye Survey,5 to generate
a target sample of 4147. A total of 35 persons aged 40
years and older were sampled in each of 120 enumera-
tion districts (EDs) to achieve this target (n = 4200).
This sample size was anticipated to give the study
adequate power to estimate the prevalence of major
eye conditions affecting older persons (Table 2). The
population aged 5 years and older comprise 92.91% of
the total population.13 Within this, 57.83% are aged 5 to
39 years and 42.17% are aged 40 years and older. We
therefore expected to find 5760 eligible people aged 5 to
39 years living alongside those aged 40 years and older,
giving a total anticipated sample of 9886 people.
Table 1. Previous population-based surveys of vision impairment
in the Caribbean.
Location Population Year
Age,
years
Sample
size, n
(response
rate, %)
Prevalence
outcomes
Barbados National 1987 40–84 4631 (82.1) Visual
impairment,4
blindness,
glaucoma,5
cataract,6 DR,7
AMD,9 refractive
error8
Cuba Local
(urban)
2005 50–99 2716 (98.4) Blindness, low
vision10
Dominican
Republic
National 2008 50–99 3873 Blindness, low
vision11
DR, diabetic retinopathy; AMD, age-related macular degeneration.
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Sampling frame
The visitation record from the 2011 Population and
Household Census was used as the sampling frame. This
was stratified into the two islands containing five regions
(one in Tobago, four in Trinidad), 21 municipalities, and
2827 mutually exclusive EDs. An ED was defined as a
geographical area comprising approximately 150 to 200
households.13 For each ED, the population size, sex dis-
tribution, age distribution, and number of buildings and
households were known.
Sampling strategy: Multi-stage randomized cluster
Primary sampling unit: The enumeration district
Random cluster sampling selected 120 EDs as the
primary sampling units, by probability-proportional-
to-size (PPS) methods.21 PPS sampling was chosen to
reduce bias in survey estimates, because the EDs dif-
fered in population size. The mean population size
was 472 people (standard deviation, SD, 189) ranging
from 1 to 1655 people. Each person in the population
had an equal probability of being selected. The dis-
tribution of the 120 clusters is shown in Figure 1, and
reflects the geospatial population density.
Secondary sampling unit: Compact segment of
households
A detailed field map of each ED was obtained from the
Central Statistics Office (CSO). Consecutive buildings were
numbered, and the ED was divided into a number of
segments determined by the population size of the ED,
with each segment containing approximately 100 people.
One segment was selected at random using Microsoft
Excel, by an investigator not directly involved in enumera-
tion. The segment’s buildings were marked clearly on the
map and given to the enumerator, who was instructed to
proceed from the first marked building to consecutively
numbered buildings.
Tertiary sampling unit: Eligible individuals
The enumerator attempted to contact everyone aged 5
years and older living in selected households to ascer-
tain eligibility. If residents were not home on the first
visit, a leaflet detailing the study was left, including a
contact telephone number for the lead survey ophthal-
mologist. Enumeration continued until 35 people aged
Figure 1. Map of Trinidad and Tobago showing distribution of the 120 National Eye Survey of Trinidad and Tobago (NESTT) clusters.
Table 2. Sample size required to give precise estimates of the
prevalence of different ocular diseases, in the National Eye
Survey of Trinidad and Tobago (NESTT).
Condition Prevalence, % Precision, 95% CI
Required
sample, n
Blindness 1.704 1.19–2.21 3455
Vision impairment 5.904 4.90–6.90 2986
Myopia 21.98 19.9–23.9 2300
Hyperopia 46.98 44.4–49.4 2143
Cataract 41.06 38.5–43.5 2082
Glaucoma 7.05 5.8–8.2 2431
Diabetic retinopathy 1.07 0.5–1.5 2130
Exudative AMD 0.509 0.25 – 0.75 4281
Based on a 2-sided type 1 error, α, of 0.05 for different prevalence rates, and
adjusted for the design effect due to clustering (1.4), but not including
anticipated non-response (for which the sample was increased by 20%).
CI, confidence interval; AMD, age-related macular degeneration.
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40 years and older in consecutive households were
enumerated. If residents were not at home or refused,
information on eligibility was sought from neighbors or
relatives. Sampling was with non-replacement. The
sample therefore included eligible people who could
not be contacted, despite at least three attempts by
both enumeration and screening teams, and those
who refused participation. This strategy was chosen to
minimize bias.
Recruitment strategy
Recruitment of participants followed a detailed strategy
that was devised following a series of pilot studies.
Eligible people who agreed to participate were given a
full verbal and written description of the study. Both
enumeration and screening teams visited each cluster
on multiple occasions, at differing times and on differ-
ent days, including weekends. If eligible for clinic, a
written appointment date and time were given and
participants were telephoned or sent an SMS message
with a reminder the preceding day. Non-attenders were
re-contacted by telephone up to three times to offer
another appointment. Telephone scripts were devel-
oped to ensure consistent delivery of key information.
People who refused enumeration were contacted by the
clinical team in a further attempt to recruit them, and if
still not interested were documented as “refused.” In
addition to an individualized communication strategy,
various additional measures were taken to increase
participation. These included information releases on
national television, in the newspaper, on the radio, on
websites and via social media (Facebook), sensitization
of eye and primary care professionals to the study, and
engagement with community leaders where these could
be identified. A separate Community Engagement and
Sensitization Strategy sensitized the general public and
participants to the ancillary NESTT genetics study.22
Staff, training and logistics
The enumeration team included a Field Supervisor, and
18 CSO-trained enumerators who had each completed
at least one national census. The clinical team included
two survey ophthalmologists, three optometrists, two
nurses, two enrolled nursing assistants, and two data
entry staff. The clinic was offered 5 days a week from 7
am to 3 pm, including Saturdays. Pairs of the clinical
team led community vision screening, during after-
noons and weekends, with assistance from six part-
time vision screeners. The genetic study sample team
included three research assistants under the supervision
of a human geneticist. The project was managed by the
lead survey ophthalmologist, and by a part-time admin-
istrator, with oversight from the Principal Investigator
and co-investigators.
Staff underwent training by the Principal
Investigator, lead survey ophthalmologist, human
geneticist, field supervisor and a low vision specialist.
The CSO-trained enumerators were given detailed enu-
meration manuals, and underwent one day of NESTT-
specific training followed by supervised fieldwork in all
clusters. The clinical and screening teams had dedicated
training for one month. Technicians from Topcon
(Topcon Corporation, Tokyo, Japan) and Medilex
(Medilex LLC, Doral, FL, USA) trained the team in
the operation of the ophthalmic equipment. A detailed
manual of operations and standard operating proce-
dures were given to team members.
The NESTT survey clinic was situated in 11 loca-
tions sequentially, within all five regions. Three loca-
tions were in Regional Health Authority (RHA)
facilities, one was within the University, and seven
were on a specially equipped NESTT mobile unit
parked at RHA facilities. The distance between the
120 clusters and the clinic ranged from 50 m to 43
km, but was generally within 10 km. Poor road quality
in some rural areas, and the sensitivity of the ophthal-
mic equipment, precluded the mobile unit from visiting
additional locations.
Survey pathway
Enumeration, consent and vision screening
The enumerators explained the purpose of the study,
ascertained eligibility, and obtained verbal consent to
participate. They collected individual contact informa-
tion and core demographic and socioeconomic data
from eligible household members, and completed a
questionnaire on each household (Table 3). Written
informed consent to participate in the survey was
obtained by the vision screening team. Children aged
5–12 years and young people aged 13–17 years were
asked to sign separate assent forms, and consent was
obtained from a legal guardian. Eligible persons with a
disability potentially affecting understanding were iden-
tified at enumeration and flagged to the survey ophthal-
mologist, who arranged to speak with the family or visit
the home to undertake a mental capacity assessment. If
they were considered to lack capacity to give informed
consent on account of a persistent impairment in the
functioning of the brain, the reason for this was docu-
mented. They were counted as a non-responder and
were not recruited to participate in the study. They
were offered an eye examination by the ophthalmolo-
gist if this was felt to serve their best interests.
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Monocular presenting distance visual acuity was
measured at eye level at 3.0 m, and binocular present-
ing near visual acuity was measured at 40.0 cm, using
logarithm of the minimum angle of resolution
(LogMAR) letter optotype charts (Precision Vision, La
Salle, IL, USA; Table 4). If the participant was not fully
literate, PV Number charts, with matching cards if
needed, were offered (Precision Vision). The partici-
pant was tested with their habitual optical correction
(spectacles or contact lenses), if applicable.23 Vision
screening was conducted in an outside but shaded
location to achieve supra-threshold chart illumination
of at least 160 cd/m2, without incident glare.23 The
Early Treatment Diabetic Retinopathy Study (ETDRS)
fast protocol was used for measurement of distance
visual acuity on the Sloan 3 metre 2000 Series Revised
ETDRS Chart, Precision Vision, La Salle, IL, USA;
Table 4).24,25 The standard ETDRS protocol was used
for measurement with the PV numbers chart, and for
measurement of near visual acuity.26 The visual acuity
score was specified in terms of the number of optotypes
correctly identified, and converted back to the LogMAR
scale later for analysis. If the participant was unable to
correctly identify the optotypes at 3.0 m they moved to
1.50 m and 0.75 m sequentially. If no optotypes could
be identified at 0.75 m, visual acuity was documented
as “counting fingers,” “hand movements,” “perception
of light” or “no perception of light.”
Survey clinic
All eligible people aged 40 years and older were invited
to attend the regional NESTT survey clinic for free
comprehensive assessment. People aged 5 to 39 years
were invited if their presenting vision was worse than
6/12 or if they had diabetes or glaucoma. On arrival,
each participant was assigned a unique survey identifi-
cation number. The clinic pathway is summarized in
Figure 2.
Questionnaires
The Epi Info software package (version 3.5.4, Centers for
Disease Control and Prevention, Atlanta, GA, USA) was
used to prospectively administer a series of structured
questionnaires. The questionnaires were developed from
question sets used in previous studies, and included
demographic,13,27,28 socioeconomic,13,29 medical and
ophthalmic history variables.27,30 Three validated patient-
reported outcome measure instruments were also
included.31–35 A supplementary questionnaire on low
vision was developed following focus group feedback
with clients registered with the Blind Welfare Association
in Trinidad and Tobago. This was administered to those
with a best-corrected visual acuity in the better-seeing eye
worse than 6/18. A supplementary questionnaire on cardi-
ovascular risk factors was administered to those who
Table 3. Variables included in structured questionnaires, National Eye Survey of Trinidad and Tobago (NESTT).
Questionnaire Variables Source of questions
Individual enumeration Sex, age, date and place of birth, ethnicity, position in household,
employment status, number of years resident in Trinidad and Tobago,
basic medical and ophthalmic history, self-reported vision status,
disabilities, and reason if not able to attend clinic for full assessment
Trinidad and Tobago Population and Housing
Census,13 RAAB instruction manual27
Household enumeration Wall and roof material, main fuel used for cooking, household ownership
status, and ownership of a set of preselected goods
Trinidad and Tobago Population and Housing
Census13
Demographic Place of birth, marital status, main language, religion, education,
employment, household income, driving history, communication access,
and health insurance status
Trinidad and Tobago Population and Housing
Census,13 International Standard Classification of
Occupations28
Socioeconomic Usage and out-of-pocket expenditure on health care over past 12 months,
usual transportation mode, informal care required on account of vision
loss, number of eye care-related sick days, and lost income in the past 12
months
UKPDS Study Healthcare Costs29
Medical and ophthalmic Past medical and ocular history, medication history and compliance,
family history, and exposure history (alcohol, tobacco, and illicit drugs)
The INTERHEART study,30 RAAB instruction
manual27
Patient-reported
outcomes
Three standardized instruments: VisQoL, the IVI and the 5-level EuroQol
questionnaires. These instruments were tested and validated in the pilot
survey. The IVI was only administered to those with best-corrected vision
worse than 6/18 in the better seeing eye, and to a randomly selected
control group of people with normal vision
VisQoL instrument,31
IVI,32,33
EuroQol34,35 questionnaires
Low vision Age at onset, duration and rate of vision loss, eye care service use history,
functional adaptations and use of low vision aids, access to low vision
services and barriers, feedback on experience using eye care services, and
potential to improve quality of life of visually impaired people
Developed through consultation with the Blind
Welfare Association, Trinidad and Tobago
Cardiovascular History of passive smoke exposure, activity level at work and during
leisure time, dietary intake of fruit and vegetables, sleep and snoring
history
The INTERHEART study30
RAAB, rapid assessment of avoidable blindness; UKPDS, United Kingdom Prospective Diabetes Study; VisQoL, Vision Quality of Life Index; IVI, Impact of Visual
Impairment.
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Table 4. Variables included in the examination, with brief outline of equipment and measurement protocol, National Eye Survey of
Trinidad and Tobago (NESTT).
Examination variable Equipment Measurement protocol
Vision screening
Distance visual acuity 3 m 2000 Series Revised ETDRS Chart, or PV Numbers acuity
vision test, Precision Vision, La Salle, IL, USA
If literate: ETDRS Fast Protocol;24,25 Beginning with the top row
the screener invited the participant to identify only one letter
per line by briefly pointing. To guarantee the same degree of
difficulty for each row, only Sloan letters of intermediate
difficulty coefficient were chosen (D, K, V, R, H). At the first letter
read incorrectly the subject was required to read the whole
preceding row. This step was repeated upward if the subject
made two or more errors. The participant then read all rows
downward, letter by letter, until the screener determined that
no further meaningful readings could be made despite urging
the subject to read or guess.
If not literate: Standard ETDRS Protocol:26 participants asked to
identify all PV numbers from the top, using a matching card if
needed, with the same stopping rules as the ETDRS-Fast
protocol
Near visual acuity Sloan 2-sided ETDRS Format Near Point Test or PV Numbers
Near Vision Card, both with 40 cm measuring cord, Precision
Vision,; Reading lamp
Standard ETDRS Protocol:26 participants asked to read all letters
from the top, with the same stopping rules as the ETDRS-Fast
protocol
Medical exam
Weight Analogue weighing scale Nurse measured to nearest kilogram with shoes removed
Height Wall-mounted tape measure with horizontal measuring level Nurse measured after removal of shoes to nearest centimeter
with participant standing against wall, and stretching their back
with their head level and feet together
Waist circumference Non-stretch fiberglass tape measure Nurse measured at the smallest circumference between the ribs
and iliac crest, to the nearest 1 cm, while standing with the
abdomen relaxed at the end of a normal expiration. Where
there was no natural waistline, measurement was taken at the
level of the umbilicus
Blood pressure and pulse
rate
HEM 907XL IntelliSense Professional Digital Blood Pressure
Monitor, Omron Corporation, Kyoto, Japan
Nurse measured blood pressure and pulse rate with participant
seated after 5 minutes of rest, using an appropriate cuff size for
the left arm circumference
Capillary blood glucose Accu Check, Roche, Basel, Switzerland Nurse swabbed finger with alcohol wipe and used safety lancet
used to obtain drop of blood. Glucose level recorded (mg/dL).
Fasting defined as having had no food and no drink except
water for 8 hours. If not fasted, recorded as random level.
Optometry exam
Auto refraction,
keratometry and
corneal topography
KR8000-PA, Topcon, Tokyo, Japan Auto refraction sphere, cylinder and axis, and corneal radius of
curvature in the horizontal and vertical meridian. One
measurement taken of each eye, and repeated if measurement
error
Spectacle prescription Model 11360 Manual Lens meter, American Optical,
Southbridge, MA, USA
Manual focimetry
Habitual reading distance Tape measure Participant asked to hold the near chart at their usual preferred
reading distance and this “habitual distance” was measured
from the corneal surface to the chart with a tape measure
Optimal near add Trial Lens Frame, Viewlight, Miami, FL, USA; Trial Lens Set
266BL, Viewlight
Trial frame fitted to the participant’s face with the distance
prescription mounted (that required to achieve at least 6/9 with
auto-refraction correction, or the lens achieving best correction).
Bracketing used to identify the plus DS lens prescription,
ranging from 0.25DS to 3.00DS, required to achieve best near
visual acuity in each eye, with the other occluded.
Contrast sensitivity Mars Letter Contrast Sensitivity Test, Precision Vision Binocular presenting contrast sensitivity at 50 cm measured
using the Mars chart, with participants in their habitual near
optical state
Ophthalmic exam
Face, adnexa, ocular
movements
Face, adnexa, globe, ocular alignment and ocular movements
documented normal or abnormal with description if abnormal
Pupils Pen torch Appearance of the pupils, direct, indirect and relative pupil
reactions documented as normal or abnormal with description if
abnormal
Anterior segment Slit lamp model BQ-900, Haag-Streit, Bern, Switzerland Any abnormalities of the anterior segment documented. Van
Herick anterior chamber depth graded: 4 (≥100%), 3 (>25–50%),
2 (25%) or 1 (<25%)36
(Continued )
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donated a saliva sample for the genetics substudy.30 The
questionnaire variables are summarized in Table 3.
Examination
The examination stations included a general medical
examination, conducted by a nurse; an eye examination
before and after dilation, including assessment of the ante-
rior chamber depth,36 lens status,37,38 and optic disc,39
conducted by an ophthalmologist; and an assessment of
vision and refractive status, conducted by an optometrist.
Additional stations included detailed ocular imaging and
measurement, with fundus photography,40 optical coher-
ence tomography, ocular biometry, and measurement of
corneal hysteresis. The examination variables, equipment
and measurement protocols are outlined in Table 4. In
addition, some participants underwent further examina-
tion based on predefined eligibility criteria. The additional
variables obtained in a subset of participants are summar-
ized in Table 5 and include glycosylated hemoglobin,41
best-corrected distance acuity, gonioscopy,39,42 automated
visual field testing and low vision assessment. Examination
findings were entered on a paper case report form (CRF) in
addition to Epi Info. People aged 5 to 39 years who were
eligible to attend the clinic had a slightly more limited
examination (Figure 2).
After the first slit-lamp examination, tropicamide 1%
(1 drop) and phenylephrine hydrochloride 2.5% (1
drop) were instilled into each eye. An additional drop
of each was instilled after a 15-minute interval if inade-
quate mydriasis was apparent. All participants had their
pupils dilated providing the iridocorneal angle was not
occludable. A normal angle was defined as a van Herick
limbal chamber depth ≥25%, or following gonioscopy
as visibility of the posterior third of the trabecular
meshwork for more than 270°.39 Dilation was avoided
in those with known allergy to mydriatic eye drops,
those with potentially occludable angles, and those who
declined dilation despite encouragement from the sur-
vey ophthalmologist.
DNA saliva sample
The survey ophthalmologist outlined the genetics sub-
study and ascertained whether adult participants were
willing to discuss participation further. If they were, the
genetics research assistant delivered comprehensive infor-
mation in a semi-structured format. Participants were free
to decide not to donate a saliva sample for extraction and
storage of DNA, to donate a sample for future genetics
studies relating to ocular and cardiovascular disease only,
or to donate a sample for both this and for addition to the
Duke University Biobank in the USA. The decision was
documented on the case report form. Written consent
was obtained, and participants were asked to fill an
Oragene tube (DNA Genotek, Ontario, Canada) with
saliva, according to the manufacturer’s instructions. A
unique barcode supplied by the Duke University
Biobank was placed on the Oragene saliva tube, on the
case report form, and on the genetics consent form.
Samples (maintained at room temperature) were shipped
Table 4. (Continued).
Examination variable Equipment Measurement protocol
Posterior segment (after
dilation)
90D MaxField and 78D MaxField High Mag, Ocular
Instruments, Bellevue, WA, USA; Slit lamp model BQ-900,
Haag-Streit
Lens graded using the LOCS III grading system, with comparison
to the standard photographic transparency.37 Nuclear color and
opalescence grades were amalgamated into a single grade.38
Vitreous, macula, retina and optic disc39 were documented as
normal or abnormal, with description if abnormal
Ocular imaging and
measurement
Intraocular pressure and
corneal hysteresis
Ocular Response Analyzer, Reichert Technologies, New York,
NY, USA
Three measurements taken of each eye, aiming to optimize the
signal to noise ratio, and the best-waveform values for two
measures of IOP (corneal compensated IOP and Goldmann-
correlated IOP) documented for each eye
Ocular biometry Lenstar LS 900R, Haag-Streit Corneal thickness, axial length, white-to-white distance, lens
thickness, anterior chamber depth, keratometry and
pupillometry. Three measurements taken of each eye
Color photographs and
optical coherence
tomography
3DOCT2000, Topcon Corporation B-scan of the temporal iridocorneal angle, radial B-scan of the
cornea, and an external color photograph. After dilation, two 45°
color photographs of ETDRS standard field 1 (centered on the
optic disc) and ETDRS standard field 2 (centered on the fovea).40
Spectral domain optical coherence tomography images
including the “macula wide,” “5-line cross” and “3D disc.”
ETDRS, Early Treatment Diabetic Retinopathy Study; DS, diopter sphere; LOCS, Lens Opacities Classification System; IOP, intraocular pressure.
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to Duke University for future DNA extraction, quantifi-
cation and genetic analyses.
Domiciliary visits
Eligible people who failed screening and were unable to
attend the clinic owing to mobility issues, frailty, illness or
care of dependents were offered a home visit by one of the
survey ophthalmologists. A limited questionnaire was
administered to obtain key data. Assessment to determine
the principal cause of vision loss included pupil reactivity,
pinhole distance visual acuity, and dilated examination
using a direct ophthalmoscope (Professional
Ophthalmoscope 3.5v, Keeler, Windsor, UK).
Service component
At the conclusion of the clinic visit participants were
given a full explanation of any findings, and a written
summary for onward referral if any abnormalities were
identified. Participants chose public or private sector
referral. Imaging results were emailed or transferred to
external memory sticks on request. Topical eye drops
were dispensed at no cost for those requiring urgent
treatment.
Quality assurance
The field supervisor coordinated the activities of the enu-
meration team. The lead survey ophthalmologist
Figure 2. National Eye Survey of Trinidad and Tobago (NESTT) clinical pathway.
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coordinated the activities of the clinical and screening
teams and audited enumeration in every cluster. If the
number of “no contact” households was >3, or if the initial
refusal rate was high, the lead survey ophthalmologist vis-
ited the cluster to review the enumeration and recruitment.
Where additional enumeration of individuals who were
skipped in error resulted in more than 35 people aged 40
years and older being included for a given cluster, this was
accounted for in the statistical analysis. Supervisory visits
weremade to the survey clinic by co-investigators to moni-
tor practices and ensure protocols were being followed.
Following the training period, inter-observer agreement
in key examination variables was analyzed using standard
statistical software (Stata release 13.1; StataCorp LP, College
Station, TX, USA). For the first 6 months of fieldwork each
pair of vision screeners included either a supervising
ophthalmologist or optometrist to provide ongoing train-
ing and quality assurance in the measurement of visual
acuity. The Moorfields Eye Hospital Reading Centre,
London,UK, graded retinal photographs andoptical coher-
ence tomography scans to provide independent validation
of the findings.
Data management
Clinic data were identifiable by survey ID number only.
In-built consistency checks in Epi Info, and validation
through duplicate entry of key variables, was used to
correct errors in data entry. The exported databases
were copied to an external hard drive daily, and the
data from the ophthalmic equipment were exported
weekly. A designated team member was responsible
Table 5. Examination procedures for a subset of participants according to specific indications, National Eye Survey of Trinidad and
Tobago (NESTT).
Examination variable Equipment Measurement protocol Indication
Glycosylated hemoglobin
A1C
Rapid point-of-care assay machine (DCA
Vantage Analyzer, Siemens, Berlin,
Germany)
Droplet of capillary blood obtained with
safety lancet. Rapid point-of-care assay
performed according to manufacturer’s
instructions
Previous diagnosis of diabetes or a
fasting blood glucose ≥126 mg/dl
(7.0 mmol/l) or a random blood
glucose >200 mg/dL (11.1 mmol/L)41
Best-corrected visual
acuity
Trial Lens Frame, Viewlight, Miami, FL,
USA; Trial Lens Set 266BL, Viewlight
Subjective refraction performed by
optometrist
Presenting distance visual acuity
worse than LogMar 0.20
(approximately 6/9) in either eye
IOP (manual) AT900 Applanation Tonometer, Haag-
Streit, Bern, Switzerland; proxymetacaine
hydrochloride 0.5%; dry strip of
fluorescein; Slit lamp model BQ-900, Haag-
Streit
Care taken to use just enough fluorescein
to obtain mires of standard thickness. IOP
measured once in each eye using
Goldmann applanation tonometer
Ocular Response Analyzer
measurement of IOP not possible
Cup-to-disc ratio
(manual)
78D MaxField High Mag, Ocular
Instruments, Bellevue, WA, USA; Slit lamp
model BQ-900, Haag-Streit
Optic disc examined at x10 magnification
and vertical dimensions of the disc and
cup measured using the eyepiece light, in
0.1 mm units, excluding areas of
peripapillary atrophy and Elschnig’s ring.
The margins of the cup were defined by
stereoscopic examination as the point of
maximum inflexion of contour, and the
height of the cup was measured as the
vertical distance between the points of
maximal centrifugal extension of the cup
between 11 and 1 o’clock and 5 and 7
o’clock.42 For small discs with no visible
cup, the measurement was taken as the
diameter of the emerging retinal vessels39
Automated cup-to-disc ratio
measurement not possible owing to
OCT machine malfunction or the
presence of significant media opacity
Gonioscopy Magna View Gonio Lens without flange,
Ocular Instruments; proxymetacaine 0.5%;
Gel tears, Bausch & Lomb Incorporated,
Rochester, NY, USA
The visibility of the four key structures was
documented
Van Herick limbal chamber depth
grade 2 or less36
Visual field test Humphrey Visual Field Analyzer II (model
740i), Carl Zeiss, Meditec AG, Jena,
Germany
24-2 SITA static, threshold-related visual
field test performed with near refractive
correction in place, prior to dilation, in
both eyes. Test reliability determined by
the instrument’s algorithm. Test repeated
once if Glaucoma Hemifield Test abnormal,
borderline, or reduced sensitivity
(1) Vertical cup-to-disc ratio ≥0.70
(2) IOP ≥21mmHg
(3) Abnormal optic disc features
suggestive of glaucoma
(4) History of diagnosed glaucoma or
ocular hypertension
Not performed in eyes with a visual
acuity worse than 0.48 Log MAR (6/
18)
Low vision tests Mars Letter Contrast Sensitivity Test,
Precision Vision, La Salle, IL, USA; MN Read
English Continuous text chart Black/White,
Precision Vision
(1) Uniocular Mars contrast sensitivity in
best-corrected state
(2) Uniocular MN Read test in best-
corrected state
Distance best-corrected visual acuity
in the better seeing eye worse than
6/18 (Log MAR 0.48)
IOP, intraocular pressure; OCT, optical coherence tomography; SITA, Swedish Interactive Threshold Algorithm; LogMAR, logarithm of the minimum angle of
resolution.
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for the secure storage of the external hard drive at all
times. The completed CRF and databases were cross-
checked monthly to check for and correct any data
entry errors. Forms were transported to a central med-
ical records office at the University of the West Indies
with restricted access for secure storage.
Security considerations and deviation from the
protocol
Trinidad and Tobago’s homicide rate was 37.9 per
100,000 in 2012.43 Criminal activity was particularly
concentrated in certain areas east of the capital, Port
of Spain, and escalated unpredictably. It was anticipated
that some randomly selected EDs might be too danger-
ous to enumerate, even for experienced enumerators
native to those districts. In this event, we planned to
replace the ED with that closest in population size
within the same municipality. In the case of EDs
being too dangerous for door-to-door vision screening,
screening was offered in safer locations (schools,
churches, community centers) within a few 100 meters
of the selected households.
Statistical methods
Statistical analyses will be performed using standard
statistical software (StataStata release 13.1). We will
explore the raw data, and the characteristics of
responders and non-responders, with simple descrip-
tive statistics. The health-related utility values (from
the EuroQol 5-dimension questionnaire, EQ5D) and
vision-related utility values (from the Vision Quality
of Life index, VisQoL) will be calculated from trans-
formation of raw scores. Crude estimates for key
outcome measures, including the prevalence of visual
impairment and common diseases, the proportion
incurring eye care costs, and the proportion suffering
decrements in utility, will be adjusted to account for
the multilevel survey design (by island and cluster),
and weighted for the response rate in each cluster. A
post-stratification adjustment will be made using the
2011 Population and Household Census for the non-
institutional population of Trinidad and Tobago
(stratified by 15 municipalities, 5-year age categories
and sex). Multilevel regression analysis, taking into
account the cluster (primary sampling unit), building
and household number (secondary sampling unit),
and individual (tertiary sampling unit), will be per-
formed for single potential explanatory variables,
which will be considered one at a time. Multilevel
multiple regression models will be estimated to con-
trol for the effects of potential explanatory and
confounding variables on the outcomes of interest.
Analyses will be done for the ≥40 years and 5–39
years age groups separately. Logistic regression will
be used for binary outcomes including responder,
vision impaired, blind and for eye disease groups.
Ordinal logistic regression will be used for expendi-
ture on eye care, and utility value. For parameter
estimation by single and multiple regression analysis,
global p-values will be obtained using the likelihood
ratio test, except when this is not possible, when the
Wald p-value will be used. A p-value ≤0.05 will be
taken to be statistically significant.
Ethical and government approval
The study adhered to the tenets of the Declaration of
Helsinki. Ethical approval was obtained from the Ethics
Committees of the University of the West Indies (May
2012), the Ministry of Health of Trinidad and Tobago
(May 2013) and Anglia Ruskin University (July 2013).
Approval for an ancillary genetic epidemiology study
was obtained from the Ethics Committees of the
University of the West Indies (May 2012), Anglia
Ruskin University (July 2013) and the Ministry of
Health of Trinidad and Tobago (July 2014). DNA sam-
ples were stored in the genetic repository at the Centre
for genetics at Duke University Medical Center, with
approval from the Duke University Institutional Review
Board.
Results
The epidemiological survey commenced in October
2013 and concluded in November 2014. Sample collec-
tion for the genetics substudy commenced in August
2014 and concluded in June 2015. Overall, 119 of 120
randomly selected clusters (primary sampling units)
were sampled as planned. One cluster in Port of Spain
had to be excluded and replaced, according to the
methodology outlined in the protocol, on account of
unacceptably high security risk. Three clusters were
categorized “very high risk” and 10 “high risk.”
Enumeration and vision screening in these commu-
nities was undertaken in safe locations and in some
cases out of sequence, at times when criminal activity
was lower. In total, a representative sample of 3410
households of 10,651 individuals were contacted, of
whom 9913 people aged 5 years and older were eligible
for recruitment (Figure 3). Figure 4 shows the geogra-
phical distribution of eligible persons, in comparison to
the 2011 census population.
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Inter-observer agreement for key examination
variables
During training, there was good agreement between obser-
vers for binary and categorical variables, including vision
category, lens grade and ocular abnormalities, which were
analyzed using a kappa coefficient (range 0.70–1.00;
Table 6).44–46 There was also acceptable agreement in the
continuous variables visual acuity and intraocular pressure,
which were analyzed using Bland-Altman limits of agree-
ment (Table 7).47–49
Discussion
The NESTT study design has a number of strengths.
First, the rigorous sampling methodology ensured
selection of a representative sample of the target
Figure 3. Multilevel selection of a nationally representative population-based sample for the National Eye Survey of Trinidad and
Tobago (NESTT).
Figure 4. Geographic distribution of National Eye Survey of Trinidad and Tobago (NESTT) sample in comparison to the 2011
Population and Household Census population.
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national population. The design effect was reduced by
inclusion of 120 clusters of 35 people aged 40 years and
older. Careful oversight of enumeration minimized the
risk of selection bias. Second, the comprehensive exam-
ination procedures will enable estimation of the preva-
lence of common, asymptomatic eye diseases and
refractive errors in people aged 40 years and older.
Third, the specialized ophthalmic equipment generated
data on several novel variables, whose significance in
relation to other variables and outcomes will be
explored. The NESTT data will provide the first nor-
mative database of ocular biometric parameters for a
Caribbean population. Fourth, like numerous other
recent epidemiological surveys of eye disease,50–52 the
NESTT included DNA sampling. Next generation
sequencing techniques will be used for genome-wide
association studies to explore novel genetic risk factors
for some of the common, complex, chronic ocular and
cardiovascular diseases, whose etiology remains elusive.
Last, the study design and reporting of the NESTT
cross-sectional survey adhere to the recommendations
outlined in the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE)
guidelines.53
There were several limiting factors in the study design.
First, resource constraints precluded the examination of a
sufficiently large sample of 5–39-year-olds to give statistical
precision around estimates in this age group. Second, the
January 2011 Population and Housing Census was the
latest available sampling frame, and was 29 months out of
date at the time of cluster selection. Deaths, births, migra-
tion in and out of the country and between areas may have
occurred during that interval, leading to population size
change within different EDs. Probability proportionate to
estimated size methods would have been preferred.
However, this approach requires a full remapping of all
households per ED, which was beyond the project’s
resources, and has seldom been achieved in previous epi-
demiological surveys of eye disease. Last, for logistical rea-
sons visual fields were not tested on all participants but on
the subsample of suspected glaucoma cases, and therefore
field loss will not be included in our definition of blindness.
The prevalence, causes, risk factors and impact of visual
impairment and blindness in the population of Trinidad
and Tobago were unknown. Regional data were sparse,3
applicable only to persons aged 40 years and older, and of
questionable relevance to this population,4 which has a
heterogeneous ethnic composition.13 The NESTT will pro-
vide novel, robust, population-based data to inform the
Table 6. Kappa coefficient for inter-observer agreement in bin-
ary and categorical examination variables, National Eye Survey
of Trinidad and Tobago (NESTT).
Observers Examination variable
Kappa (p-
value)
All vision screeners Monocular distance visual
acuity
Visual acuity ≥6/6
Visual acuity <6/6 and ≥6/18
Visual acuity <6/18
0.81 (<0.0001)
0.76 (<0.0001)
0.85 (<0.0001)
Two survey
ophthalmologists
Lens opacity LOCS IIIa
Nuclear
Cortical
Posterior subcapsular
0.70 (<0.0001)a
0.75 (<0.0001)a
0.86 (<0.0001)a
Two survey
ophthalmologists
Van Herick limbal chamber
depth
0.79 (<0.0002)
Two survey
ophthalmologists
Pupil normal or abnormal 1.00 (<0.0001)
Two survey
ophthalmologists
Macula normal or abnormal 1.00 (<0.0001)
Two survey
ophthalmologists
Retina normal or abnormal 1.00 (<0.0001)
Two survey
ophthalmologists
Optic disc normal or abnormal 0.87 (<0.0001)
aKappa weighting: 1, 0.6, 0.3, 0, 0, 0, 0.
20 eyes of 20 volunteers included in analysis.
LOCS, Lens Opacities Classification System.
Table 7. Bland-Altman limits of agreement in the measurement of continuous examination variables, National Eye Survey of Trinidad
and Tobago (NESTT).
Variable (unit) Observer N
Mean (SD) and difference in
mean (SD)
Bland-Altman upper and lower limits of
agreement (95% CI)
Distance visual acuity
(number of letters
correctly
identified)
Trainer (ophthalmologist)
versus
Each vision screener
20 left
eyes
Trainer: 56.4 letters (9.0),
range 33–66
Most dissimilar screener:
55.4 letters (9.5), range
32–66
Mean difference: 1.1 letters
(3.1), range −6–9
Upper limit: 7 letters (95% CI 5, 10)
Lower limit: −5 letters (95% CI −3, −8)
100% within 10 letters (2 lines) of the
trainer’s measure; 85% within 5 letters (1
line)
IOP (mmHg) Manual GAT
versus
Automated Goldmann-correlated IOP
measured by the Ocular Response Analyzer
(g-IOP)
101
left
eyes
GAT: 15.8 mmHg
(4.1 mmHg), range
9–36 mmHg
g-IOP: 16.0 mmHg
(4.8 mmHg), range
7–39 mmHg
Mean difference:
0.26 mmHg (2.2 mmHg) (p =
0.25)
Upper limit: 4.2 mmHg (95% CI 3.4,
4.9 mmHg)
Lower limit: −4.7 mm Hg (95% CI −5.4,
−3.9 mmHg)
83.2% of GAT IOP within 2 mmHg of g-IOP
SD, standard deviation; CI, confidence interval; IOP, intraocular pressure; GAT, Goldman applanation tonometry.
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rational development of a national eye care strategy that
aims to address the unmet needs of the population and
reduce the burden of avoidable vision loss.
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